Modalities
Solutions Overview
Every modality brings its own process demands. Repligen supports antibodies and recombinant proteins, viral vectors, mRNA, plasmid DNA, ADCs, and emerging platforms with connected solutions across mixing, single-use fluid management, chromatography, filtration, and real-time analytics — from development through GMP.
What are biologic modalities?
Biologic modalities are the different classes of therapeutics manufactured in bioprocessing — from established monoclonal antibodies and recombinant proteins to viral vectors, mRNA, plasmid DNA, antibody-drug conjugates, and cell-based platforms.
Each modality places different demands on the process. Viral vectors need gentle handling to protect particle integrity. mRNA depends on efficient purification and formulation. ADCs introduce conjugation and solvent compatibility considerations. Recognizing those differences early makes processes easier to scale and transfer.
Repligen helps bioprocess, MSAT, and manufacturing teams work across all of them — with mixing, fluid management, purification, filtration, and process analytics selected for the specific requirements of each modality, and scalable from benchtop process development through commercial GMP manufacturing.
Expertise Behind Every Modality
From established biologics to emerging platforms, Repligen helps teams solve real process challenges — with hands-on support from early development through commercial GMP manufacturing.
Global field application support
Development to commercial GMP
Recognized expertise in gene therapy, oncolytics, and vaccines
Quality documentation available
Global field application
Development to commercial GMP
Recognized expertise in gene therapy, oncolytics, and vaccines
Quality documentation available
Explore Modailities
Antibodies & Recombinant Proteins
Upstream intensification, clarification, chromatography, and UF/DF for mAbs, fragments, Fc and albumin fusions, and protein vaccines.
mRNA
With the proven success of mRNA-based vaccines in addressing the COVID-19 pandemic, mRNA technology is at the forefront of transforming the world of medicine. Clinical trials are ongoing to develop both vaccines and therapies to treat infectious diseases and even cancer.
Viral Vectors
Support AAV, lentiviral, and next-generation vector production with intensified upstream and downstream solutions.
Antibody-Drug Conjugates
Support across the ADC workflow — from antibody intermediate production through buffer exchange, aggregation control, and formulation.
Not sure which approach fits your modality?
Tell us about your process and a field application specialist will help you map the right workflow.
Frequently asked questions
Quick answers on how bioprocessing needs differ across modalities.
Repligen supports bioprocessing for monoclonal antibodies and recombinant proteins, viral vectors, mRNA, plasmid DNA, antibody-drug conjugates, and emerging cell-based modalities.
Each modality stresses the process differently. Viral vectors require gentle handling to preserve particle integrity, mRNA depends on efficient purification and formulation, and ADCs add conjugation and solvent considerations after the antibody is made.
AAV is most commonly used for in vivo gene therapy, while lentivirus is widely used to modify cells ex vivo, as in CAR-T therapies. Both require careful control of recovery and particle integrity through purification.
Plasmid DNA is the template used to produce mRNA by in vitro transcription and to generate viral vectors. Consistent pDNA quality early on makes downstream processing more predictable.
ADCs combine a monoclonal antibody with a cytotoxic payload, so manufacturing adds conjugation, solvent compatibility, buffer exchange, and aggregation control on top of standard antibody purification.
Repligen supports emerging and cell-based modalities with flexible, single-use fluid management, purification, and analytics that adapt as processes evolve.
Enabling Advanced Bioprocessing
From established biologics to emerging platforms, today's therapeutic modalities are transforming disease treatment. Repligen solutions are designed to help you overcome process challenges and drive the production of innovative therapies across a broad range of modalities, powering precision oncology, cell and gene therapies, and more.